Radioactive drug targets tough lung cancers in early trial
Disease control
Ongoing
This early-phase study tests a new radioactive drug (225Ac-ABD147) in people with small cell lung cancer or large cell neuroendocrine lung cancer whose cancer has grown after platinum chemotherapy. The main goals are to check safety, find the best dose, and see if the drug can sh…
Phase: PHASE1 • Sponsor: Abdera Therapeutics Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC